Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site

Novartis AG is investing billions in its US footprint and has just broken ground on a new radioligand therapy site in Texas. What this means for the pharma giant’s growth profile and why the stock remains closely watched by US investors.

Novartis AG is sharpening its US growth profile with a fresh manufacturing project: on May 7, 2026, the healthcare group broke ground on a new 46,000 sq. ft radioligand therapy site in Denton, Texas, part of a wider USD 23 billion investment plan in US research and production over five years, according to Novartis press release as of 05/07/2026.

For investors, the project matters because the Denton plant will be Novartis’ fifth radioligand therapy manufacturing site in the United States and is expected to become operational in 2028, underscoring management’s intention to manufacture key medicines for US patients within the country and strengthen supply resilience, as highlighted in the same company announcement, according to Novartis press release as of 05/07/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, innovative medicines
• Headquarters/country: Basel, Switzerland
• Core markets: United States, Europe, global
• Key revenue drivers: Innovative patented medicines, oncology, cardiovascular and immunology therapies
• Home exchange/listing venue: SIX Swiss Exchange, New York Stock Exchange (ADR: NVS)
• Trading currency: Swiss franc on SIX, US dollar for ADRs

Novartis AG: core business model

Novartis is a global healthcare group focused on prescription medicines, with a portfolio spanning oncology, cardiovascular, immunology, neuroscience and other specialty indications. The company positions itself as an innovative medicines pure play after a series of portfolio moves over recent years that shifted its focus toward patented therapies and higher-margin segments. This strategic concentration aims to improve profitability and sharpen the corporate profile for investors concentrating on large-cap biopharma.

The group’s business model relies on intensive research and development, multi-year clinical programs and regulatory approvals to bring new medicines to market. Once approved, products benefit from patent protection that typically supports premium pricing and strong cash flows for several years. Novartis reinvests a significant portion of these cash flows into its pipeline to sustain long-term growth, while also returning cash to shareholders through dividends and, depending on the period, share repurchases when authorized by the board.

In the US market, Novartis has become a key supplier of specialty medicines, particularly in oncology and cardiovascular disease, where demand is driven by aging populations and the rising prevalence of chronic conditions. The company’s emphasis on radioligand therapies and other advanced platforms reflects a strategic push into technologies that can offer targeted treatment and potential differentiation versus competitors. For US investors, this creates an investment case centered on innovation intensity, pipeline execution and pricing resilience in a changing reimbursement environment.

Main revenue and product drivers for Novartis AG

Novartis generates the bulk of its revenue from innovative medicines, including key oncology and cardiometabolic products. While individual product names and sales figures fluctuate from year to year, the broad revenue mix is dominated by therapies that address large, chronic disease areas with high unmet medical need. This mix supports recurring demand and offers leverage to demographic trends, particularly in developed markets such as the United States and Europe.

Radioligand therapies, the focus of the new Denton site, are becoming an increasingly important part of the company’s oncology franchise. By investing in dedicated US manufacturing capacity, Novartis aims to secure supply for current and potential future radioligand products, reducing logistics risk and positioning itself for broader adoption if clinical data and regulatory decisions remain favorable. The decision to build a fifth US RLT site highlights management’s expectation that this platform will contribute meaningfully to medium- and long-term revenue.

Beyond radioligands, growth is supported by newer cardiovascular and immunology medicines, where Novartis seeks to capture share in expanding markets. These therapies often command premium pricing but also face cost pressure from payers, biosimilars and generics once exclusivity expires. The company’s ability to refresh its portfolio with new launches and lifecycle management strategies is therefore central to maintaining and expanding its revenue base. For US investors, monitoring product launch trajectories and payer coverage decisions is a key part of tracking the stock’s fundamental story.

Novartis AG’s USD 23 billion US investment program

The Denton announcement is part of a broader capital expenditure program. In April 2025, Novartis committed USD 23 billion over five years to expand its US research and manufacturing footprint, including seven new and three expanded facilities across the country that are already under construction, according to Novartis press release as of 05/07/2026. The program is designed to ensure that all key medicines for US patients are manufactured domestically to support supply resilience.

This US-centric investment has several potential implications for shareholders. First, it underscores the strategic importance of the US market for Novartis, which is a major source of revenue and a leading driver of profitability for global pharma companies. Second, by localizing production, Novartis may reduce exposure to cross-border logistics risks and regulatory uncertainties linked to international supply chains. Third, large-scale capex in advanced manufacturing could enhance productivity over time, although it also weighs on free cash flow in the construction phase and introduces execution risk if projects face delays or cost overruns.

The Denton site in Texas is expected to become operational in 2028 and create new US-based roles in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in the surrounding communities, as mentioned by the company, according to Novartis press release as of 05/07/2026. For long-term investors, the key question will be how effectively these investments translate into reliable supply, regulatory compliance and commercial flexibility across the company’s US portfolio.

Financial scale and valuation signals

Novartis ranks among the world’s larger healthcare companies by market value. As of May 2026, its equity market capitalization was estimated at about USD 285.77 billion, placing it around 54th globally by market cap, according to CompaniesMarketCap data as of 05/2026. This scale provides access to capital markets, supports extensive R&D programs and offers room for selective acquisitions or partnerships when strategic opportunities arise.

Independent screeners have highlighted that Novartis shows strong profitability metrics and high margins relative to many other listed companies. MarketScreener described its margins before interest, taxes, depreciation and amortization as particularly high and noted that margins are among the highest on the stock exchange list, reflecting a core activity that delivers solid profits, according to MarketScreener analysis as of 2026. At the same time, the same analysis pointed out that on an enterprise value to sales basis, the stock could appear expensive compared with some peers, which introduces valuation risk if growth or margins disappoint.

For US investors evaluating the NYSE-listed ADRs, such metrics are part of a broader picture that also includes currency exposure to the Swiss franc, the company’s dividend policy and potential capital allocation choices. High historical margins may offer a cushion against pricing headwinds, but they can also influence market expectations. If investors price in continued high profitability and sustained growth, any setback in R&D, regulation or competition could have an outsized effect on the share price.

Industry trends and competitive position

Novartis operates in a highly competitive and regulated global pharmaceutical market. Key rivals include other big pharma and biotech players with significant R&D budgets and global commercial footprints. Industry trends such as the rise of biologics, gene and cell therapies, and targeted radioligand treatments are reshaping the therapeutic landscape, with companies racing to secure first-mover advantages in promising indications. Novartis’ focus on radioligand therapy and other advanced platforms positions it within these innovation-driven segments, but also exposes it to the risks inherent in emerging technologies.

Regulatory scrutiny remains an important factor, particularly in the United States, where agencies closely monitor drug safety, pricing practices and manufacturing quality. Any compliance issues or safety signals could lead to product interruptions or reputational damage. Conversely, successful approvals in major indications can unlock large commercial opportunities and extend the life cycle of key products. Novartis must balance aggressive innovation with risk management and quality systems that meet stringent regulatory standards across all its sites, including the new US facilities.

Another structural trend is the increasing pressure from payers and policymakers to manage healthcare costs. This can affect pricing power and reimbursement terms, especially for high-cost specialty medicines. Novartis, like its peers, faces ongoing negotiations with insurers, pharmacy benefit managers and national health systems. Its ability to demonstrate clinical value, real-world outcomes and cost-effectiveness will help determine how its therapies are positioned on formularies and how widely they are adopted, particularly in the US market where payer mix and policy are complex and subject to change.

Why Novartis AG matters for US investors

For US-based investors, Novartis offers exposure to a large-cap, globally diversified pharmaceutical business with a meaningful operational footprint in the United States. The stock trades as an American Depositary Receipt on the New York Stock Exchange under the ticker NVS, allowing investors to access the company in US dollars and within US brokerage accounts. This can make the stock more accessible for retail investors who may not trade directly on European exchanges.

The company’s expanding US manufacturing base, including the Denton radioligand site and other ongoing projects, reinforces its role in the American healthcare system as a supplier of advanced oncology and specialty therapies. This domestic build-out may become increasingly relevant in light of policy discussions around supply chain security, reshoring of critical manufacturing and the resilience of the US healthcare infrastructure. For investors concerned about geopolitical or logistical disruptions, a stronger US footprint could be seen as a way for Novartis to mitigate some operational risks over the long term.

In addition, Novartis’ research presence in the United States places it close to leading academic centers, biotech clusters and potential collaboration partners. Access to talent and innovation ecosystems can influence the depth and pace of pipeline development. As new data emerge from clinical trials and regulatory decisions unfold, US investors will likely focus on how these milestones interact with the company’s manufacturing readiness and commercial strategy, including the ability of sites like Denton to support future demand if key radioligand assets achieve broader adoption.

Conclusion

Novartis AG is reinforcing its US strategic importance with a new radioligand therapy site in Texas, embedded in a USD 23 billion multi-year investment program aimed at expanding research and manufacturing capacity in the country. The company combines scale, high historical margins and a focus on innovative medicines, while also facing the usual sector challenges of pipeline risk, regulation and pricing pressure. For US investors accessing the ADRs, the story hinges on how effectively Novartis converts its innovation platforms and capital expenditures into sustainable revenue growth and resilient supply, balanced against valuation considerations and the competitive dynamics of global pharmaceuticals.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.